{
  "paper_metadata": {
    "pmid": "32749600",
    "title": "Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers",
    "extraction_summary": "Extracted genetic variant information for the TTR gene, including penetrance data for affected and unaffected carriers."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": null,
      "protein_notation": null,
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 62,
        "demographics": "Mean age 59.8 years (\u00b1 12), 34 men, 28 women",
        "phenotype": "Hereditary transthyretin amyloidosis (ATTRv), with manifestations including carpal tunnel syndrome and polyneuropathy"
      },
      "penetrance_data": {
        "total_carriers_observed": 62,
        "affected_count": 34,
        "unaffected_count": 28,
        "uncertain_count": null,
        "penetrance_percentage": 54.84,
        "age_dependent_penetrance": [
          {
            "age_range": "36-86 years",
            "penetrance_percentage": 54.84,
            "carriers_in_range": 62,
            "affected_in_range": 34
          }
        ]
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": 64,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "Axonal polyneuropathy",
          "evidence_sentence": "According to the neurophysiologic findings, 34 (55%) ATTRv subjects (mean age 64.4, range 36\u201386, mean BMI 24.2, range 14\u201338) were diagnosed with axonal polyneuropathy."
        },
        {
          "individual_id": "P2",
          "age_at_evaluation": 54,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "unaffected",
          "phenotype_details": "Pre-symptomatic carrier with no symptoms or signs of systemic amyloidosis",
          "evidence_sentence": "28 subjects (45%) did not show symptoms or signs of systemic amyloidosis including polyneuropathy."
        }
      ],
      "functional_data": {
        "summary": "Nerve ultrasound evaluation showed differences in cross-sectional area between affected and unaffected carriers.",
        "assays": [
          "Nerve ultrasound",
          "Neurophysiological studies"
        ]
      },
      "segregation_data": "Segregation with disease in families is implied but not explicitly stated.",
      "population_frequency": null,
      "evidence_level": "Moderate",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The most frequent mutations were Phe64Leu, Val30Met, and Glu89Gln.",
      "key_quotes": [
        "The most frequent mutations were Phe64Leu (22 subjects), Val30Met (13 subjects), Glu89Gln (11 subjects).",
        "Prevalence of ATTRv polyneuropathy across the different mutations is reported in Table 2."
      ]
    }
  ],
  "tables_processed": [
    {
      "table_name": "Table 1",
      "table_caption": "TTR gene mutations in our ATTRv populations",
      "variants_extracted": 3
    },
    {
      "table_name": "Table 2",
      "table_caption": "Prevalence and severity of ATTRv polyneuropathy (PN) in the different genotypes",
      "variants_extracted": 6
    }
  ],
  "extraction_metadata": {
    "total_variants_found": 3,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data was extracted from the main text and tables."
  }
}